source
- 92Bio revives a T cell engager it had transferred to AmgenA small California startup is reviving an experimental T cell engager that its scientists originally developed but had handed off to Amgen years ago. After repeatedly saying it would bring the drug…Endpoints · 29d ago↗ source
- Angitia ends Phase 3 in disc disease; Abivax targets $800M on colitis data🩻 Angitia Biopharmaceuticals drops Phase 3: The US and China biotech terminated a late-stage trial of AGA111 in patients with degenerative disc disease who had a lumbar interbody fusion, according…Endpoints · 29d ago↗ source
- Ipsen to scoop up Memo Therapeutics and its kidney infection drugIpsen is on an M&A roll. The French drugmaker announced its second deal of the week, saying it would buy Memo Therapeutics and its drug candidate called potravitug for a viral ...